Revlimid (lenalidomide) — coverage criteria
Defines accepted oncology indications, dosing limits, contraindications, and evidence requirements for lenalidomide (Revlimid) for Neighborhood Health Plan of Rhode Island members; applies to providers submitting authorization requests processed by Evolent.
Converted to new Evolent guideline template and replaced prior UM ONC_1193 Revlimid policy.
Added new indication: MM initial therapy for transplant-ineligible members in combination with isatuximab-irfc + bortezomib +/- steroid.
Updated single dose limits in exclusion criteria.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.